RTS,S/AS01疟疾疫苗与麻疹、风疹和黃热疫苗在加纳儿童中联合接种的免疫原性与安全性:一项IIIb期、多中心、非劣效性、随机、开放、对照试验
该IIIb期多中心随机开放对照试验在709名加纳儿童中评估RTS,S/AS01疟疾疫苗与黃热疫苗及麻疹-风疹联合疫苗联合接种的免疫原性和安全性,结果显示联合接种组对疟疾和乙肝表面抗原的抗体反应非劣效于单独接种RTS,S/AS01组,对麻疹、风疹和黃热抗原的抗体反应非劣效于单独接种EPI疫苗组,所有疫苗安全性可接受。
要点
- RTS,S/AS01与黃热疫苗及麻疹-风疹联合疫苗在9月龄联合接种不损害对任何疫苗抗原的免疫应答。
- 联合接种组与单独接种组相比,所有疫苗安全性特征临床可接受。
- RTS,S/AS01可在6月龄与维生素A补充及9月龄EPI访视时与黃热疫苗和麻疹-风疹联合疫苗同时接种。
核心结论
- RTS,S/AS01可在6月龄与维生素A补充及9月龄EPI访视时与黃热疫苗和麻疹-风疹联合疫苗联合接种,不损害对任何疫苗抗原的免疫应答,也无负面安全性影响。
研究设计与样本
- IIIb期、多中心、非劣效性、随机、开放、对照试验(NCT02699099),709名加纳儿童按1:1:1随机分为三组。
- RTS,S联合接种组在6、7.5和9月龄接种RTS,S/AS01,并在9月龄接种黃热疫苗和麻疹-风疹联合疫苗。
- RTS,S单独接种组在6、7.5和9月龄接种RTS,S/AS01,并在10.5月龄接种黃热疫苗和麻疹-风疹联合疫苗。
- 对照组在9月龄接种黃热疫苗和麻疹-风疹联合疫苗,并将在10.5、11.5和12.5月龄接种RTS,S/AS01。
- 所有儿童在6月龄接受维生素A补充;安全性评估至研究第4.5个月。
主要发现
- RTS,S/AS01与黃热疫苗和麻疹-风疹联合疫苗联合接种组对比单独接种RTS,S/AS01组,抗环子孢子蛋白和抗乙肝病毒表面抗原的抗体应答非劣效性成立。
- RTS,S/AS01与黃热疫苗和麻疹-风疹联合疫苗联合接种组对比单独接种黃热疫苗和麻疹-风疹联合疫苗组,对麻疹、风疹和黃热抗原的抗体应答非劣效性成立。
- 所有组中所有疫苗的安全性特征临床可接受。
关键数值与推荐
- 采用预先设定的非劣效性标准评估联合接种后1个月对疫苗抗原的免疫应答。
临床怎么用
- 原文结论指出RTS,S/AS01可在6月龄与维生素A补充及9月龄EPI访视时与黃热疫苗和麻疹-风疹联合疫苗联合接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To optimize vaccine implementation visits for young children, it could be efficient to administer the first RTS,S/AS01 malaria vaccine dose during the Expanded Programme on Immunization (EPI) visit at 6 months of age together with Vitamin A supplementation and the third RTS,S/AS01 dose on the same day as yellow fever (YF), measles and rubella vaccines at 9 months of age. We evaluated the safety and immunogenicity of RTS,S/AS01 when co-administered with YF and combined measles-rubella (MR) vaccines. METHODS: In this phase 3b, open-label, controlled study (NCT02699099), 709 Ghanaian children were randomized (1:1:1) to receive RTS,S/AS01 at 6, 7.5 and 9 months of age, and YF and MR vaccines at 9 or 10.5 months of age (RTS,S coad and RTS,S alone groups, respectively). The third group received YF and MR vaccines at 9 months of age and will receive RTS,S/AS01 at 10.5, 11.5 and 12.5 months of age (Control group). All children received Vitamin A at 6 months of age. Non-inferiority of immune responses to the vaccine antigens was evaluated 1 month following co-administration versus RTS,S/AS01 or EPI vaccines (YF and MR vaccines) alone using pre-defined non-inferiority criteria. Safety was assessed until Study month 4.5. RESULTS: Non-inferiority of antibody responses to the anti-circumsporozoite and anti-hepatitis B virus surface antigens when RTS,S/AS01 was co-administered with YF and MR vaccines versus RTS,S/AS01 alone was demonstrated. Non-inferiority of antibody responses to the measles, rubella, and YF antigens when RTS,S/AS01 was co-administered with YF and MR vaccines versus YF and MR vaccines alone was demonstrated. The safety profile of all vaccines was clinically acceptable in all groups. CONCLUSIONS: RTS,S/AS01 can be co-administered with Vitamin A at 6 months and with YF and MR vaccines at 9 months of age during EPI visits, without immune response impairment to any vaccine antigen or negative safety effect.
引用
- Asante KP, Ansong D, Kaali S, et al. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial. Vaccine. 2020. PMID: 32192811. doi:10.1016/j.vaccine.2020.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。